Velavigo Bio Inc
Clinical trials sponsored by Velavigo Bio Inc, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug VBC101 targets tough cancers in early trial Results expected Jul 2027 (estimated)
-
Can a Dual-Targeting drug shrink Hard-to-Treat tumors?
Disease control Not yet recruitingThis trial tests VBC117, an investigational drug designed to attach to two proteins found on tumor cells and deliver a toxic payload directly to them. The study enrolls adults with advanced or metastatic solid tumors that have not responded to standard treatments. The goal is to …
Phase 1/2 • Sponsor: VelaVigo Bio Inc • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New Dual-Targeting drug VBC106 takes aim at Hard-to-Treat cancers
Disease control Not yet recruitingThis trial tests an experimental drug called VBC106 in people with advanced solid tumors that have not responded to standard treatments. VBC106 is designed to target two proteins (FRα and MSLN) found on some cancer cells, delivering a toxic payload directly to the tumor. The stud…
Phase 1/2 • Sponsor: VelaVigo Bio Inc • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC